Bausch & Lomb is one of the largest vision care companies in the US. Bausch spun off from its former parent company, Bausch Health, in 2022 and it now operates in three segments: vision care, surgical ...
The first of what is hoped to be an annual study of the region's sector is positive but lack of funding, laboratory space and ...
Australia’s Recce Pharmaceuticals has announced positive data from a Phase II trial evaluating RECCE 327 Topical Gel (R327G) ...
Recce Pharmaceuticals’ synthetic gel successfully treated a range of skin infections in a phase 2 trial, leading the ...
D. Boral Capital reiterated their buy rating on shares of UroGen Pharma (NASDAQ:URGN – Free Report) in a report released on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $25.00 ...
AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...
The Phase II trial saw Recce 327 achieving all primary and secondary endpoints as the company looks to launch a Phase III trial.
Recce Pharmaceuticals Ltd has received positive findings from a Phase II clinical trial evaluating RECCE® 327 Topical Gel (R327G) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI), ...
Stockhead on MSN3d
Recce soars on phase II skin infection trial resultsRecce Pharmaceuticals up ~9% after successful phase II clinical trial assessing efficacy and safety of R327G in patients with ...
Recce Pharmaceuticals Ltd (ASX:RCE) has yielded positive data on the effectiveness of its topical gel in treating Acute ...
Available exclusively through Fox Pharma, the latest aesthetic innovation, VITARAN harnesses the power of trout DNA for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback